retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Beyond GLP-1: Retatrutide's triple-agonist mechanism

As well as turning down the dial on food noise, some users have reported positive effects on mood, while others feel emotionally flat

(2021) of the CVOTs found that the GLP-1 RAs are associated with a significant 14% relative risk reduction in terms of major adverse cardiovascular events (MACE, a standard 3-component composite endpoint) (hazard ratio [HR] 0.86

The team then showed that mice whose gut microbiota had been depleted using broad-spectrum antibiotics did not experience liraglutides antidepressant effects, pointing to a key role for the microorganisms in the gut

High cortisol levels can interfere with appetite control and glucose metabolism